Page 24 - 2021_06-Haematologica-web

Y.F. van Lier et al.
2020;581(7809):475-479.
76. Hang S, Paik D, Yao L, et al. Bile acid
metabolites control TH17 and Treg cell dif- ferentiation. Nature. 2019;576(7785):143- 148.
77. Reikvam H, Gronningsaeter IS, Mosevoll KA, Lindas R, Hatfield K, Bruserud O. Patients with treatment-requiring chronic graft versus host disease after allogeneic stem cell transplantation have altered meta- bolic profiles due to the disease and immunosuppressive therapy: potential implication for biomarkers. Front Immunol. 2017;8:1979.
78.Michonneau D, Latis E, Curis E, et al. Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nat Commun. 2019;10(1):5695.
79. Joshi NM, Hassan S, Jasani P, et al. Bile acid malabsorption in patients with graft-versus- host disease of the gastrointestinal tract. Br J Haematol. 2012;157(3):403-407.
80. Ruutu T, Juvonen E, Remberger M, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant. 2014;20(1):135-138.
81.Webb BJ, Brunner A, Lewis J, Ford CD, Lopansri BK. Repurposing an old drug for a new epidemic: ursodeoxycholic acid to pre- vent recurrent Clostridioides difficile infec- tion. Clin Infect Dis. 2019;68(3):498-500.
82. Weber D, Oefner PJ, Dettmer K, et al. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(8):1087-1092.
83. Rearigh L, Stohs E, Freifeld A, Zimmer A. De-escalation of empiric broad spectrum antibiotics in hematopoietic stem cell trans- plant recipients with febrile neutropenia. Ann Hematol. 2020;99(8):1917-1924.
84. Kaleko M, Bristol JA, Hubert S, et al. Development of SYN-004, an oral beta-lac- tamase treatment to protect the gut micro- biome from antibiotic-mediated damage and prevent Clostridium difficile infection. Anaerobe. 2016;41:58-67.
85. de Gunzburg J, Ghozlane A, Ducher A, et al. Protection of the human gut microbiome from antibiotics. J Infect Dis. 2018;217(4): 628-636.
86. Yoshifuji K, Inamoto K, Kiridoshi Y, et al. Prebiotics protect against acute graft-versus- host disease and preserve the gut microbiota in stem cell transplantation. Blood Adv. 2020;4(19):4607-4617.
87. Iyama S, Sato T, Tatsumi H, et al. Efficacy of enteral supplementation enriched with glut- amine, fiber, and oligosaccharide on mucos- al injury following hematopoietic stem cell transplantation. Case Rep Oncol. 2014;7(3): 692-699.
88. Ladas EJ, Bhatia M, Chen L, et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(2):262-266.
89. Sadanand A, Newland JG, Bednarski JJ. Safety of probiotics among high-risk pedi- atric hematopoietic stem cell transplant recipients. Infect Dis Ther. 2019;8(2):301- 306.
90. Gerbitz A, Schultz M, Wilke A, et al. Probiotic effects on experimental graft-ver- sus-host disease: let them eat yogurt. Blood. 2004;103(11):4365-4367.
91. Le Bastard Q, Ward T, Sidiropoulos D, et al. Fecal microbiota transplantation reverses
92.
antibiotic and chemotherapy-induced gut dysbiosis in mice. Sci Rep. 2018;8(1):6219. Battipaglia G, Malard F, Rubio MT, et al. Fecal microbiota transplantation before or after allogeneic hematopoietic transplanta- tion in patients with hematologic malignan- cies carrying multidrug-resistance bacteria. Haematologica. 2019;104(8):1682-1688.
cance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38(1):62-69.
108. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associ- ated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-439.
109.Robin F, Paillard C, Marchandin H, Demeocq F, Bonnet R, Hennequin C. Lactobacillus rhamnosus meningitis follow- ing recurrent episodes of bacteremia in a child undergoing allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2010;48(11):4317-4319.
110.Gorshein E, Wei C, Ambrosy S, et al. Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoiet- ic stem cell transplantation. Clin Transplant. 2017;31(5).
111. DeFilipp Z, Peled JU, Li S, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversi- ty. Blood Adv. 2018;2(7):745-753.
112. Bilinski J, Grzesiowski P, Sorensen N, et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut coloniza- tion with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis. 2017;65(3):364-370.
113. Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14(6):E161-165.
114. de Castro CG Jr, Ganc AJ, Ganc RL, Petrolli MS, Hamerschlack N. Fecal microbiota transplant after hematopoietic SCT: report of a successful case. Bone Marrow Transplant. 2015;50(1):145.
115. Mittal C, Miller N, Meighani A, Hart BR, John A, Ramesh M. Fecal microbiota trans- plant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lym- phoma. Bone Marrow Transplant. 2015;50(7):1010.
116. Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D. Fecal microbiota trans- plantation for recurrent Clostridium difficile infection in hematopoietic stem cell trans- plant recipients. Transpl Infect Dis. 2016;18(4):628-633.
117.Bluestone H, Kronman MP, Suskind DL. Fecal microbiota transplantation for recur- rent Clostridium difficile infections in pedi- atric hematopoietic stem cell transplant recipients. J Pediatric Infect Dis Soc. 2018;7(1):e6-e8.
118.Moss EL, Falconer SB, Tkachenko E, et al. Long-term taxonomic and functional diver- gence from donor bacterial strains following fecal microbiota transplantation in immuno- compromised patients. PLoS One. 2017;12 (8):e0182585.
119.Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host dis- ease of the gut. Blood. 2016;128(16):2083- 2088.
120.Spindelboeck W, Schulz E, Uhl B, et al. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host- disease. Haematologica. 2017;102(5):e210- e213.
121.Qi X, Li X, Zhao Y, et al. Treating steroid
93.InnesAJ,MullishBH,FernandoF,etal.Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organ- ism-related non-relapse mortality. Bone Marrow Transplant. 2017;52(10):1452-1454.
94. Kolodziejczyk AA, Zheng D, Elinav E. Diet- microbiota interactions and personalized nutrition. Nat Rev Microbiol. 2019;17(12): 742-753.
95. Li X, Lin Y, Li X, et al. Tyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome. EBioMedicine. 2020;61:103048.
96. D'Amico F, Biagi E, Rampelli S, et al. Enteral nutrition in pediatric patients undergoing hematopoietic SCT promotes the recovery of gut microbiome homeostasis. Nutrients. 2019;11(12):2958.
97. Andersen S, Staudacher H, Weber N, et al. Pilot study investigating the effect of enteral and parenteral nutrition on the gastrointesti- nal microbiome post-allogeneic transplanta- tion. Br J Haematol. 2020;188(4):570-581.
98. Gonzales F, Bruno B, Alarcon Fuentes M, et al. Better early outcome with enteral rather than parenteral nutrition in children under- going MAC allo-SCT. Clin Nutr. 2018;37(6 Pt A):2113-2121.
99. Beckerson J, Szydlo RM, Hickson M, et al. Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. Clin Nutr. 2019;38(2):738-744.
100.Segal L, Opie RS. A nutrition strategy to reduce the burden of diet related disease: access to dietician services must comple- ment population health approaches. Front Pharmacol. 2015;6:160.
101. Johnson AJ, Vangay P, Al-Ghalith GA, et al. Daily sampling reveals personalized diet- microbiome associations in humans. Cell Host Microbe. 2019;25(6):789-802.
102. McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014;4(8):e005047.
103. Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution Is impaired by probiotics and improved by autologous FMT. Cell. 2018;174(6):1406-1423.
104. Cohen SA, Woodfield MC, Boyle N, Stednick Z, Boeckh M, Pergam SA. Incidence and outcomes of bloodstream infections among hematopoietic cell trans- plant recipients from species commonly reported to be in over-the-counter probiotic formulations. Transpl Infect Dis. 2016;18 (5):699-705.
105.Ambesh P, Stroud S, Franzova E, et al. Recurrent Lactobacillus bacteremia in a patient with leukemia. J Investig Med High Impact Case Rep. 2017;5(4): 2324709617744233.
106. Mehta A, Rangarajan S, Borate U. A caution- ary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sep- sis in a patient with mantle cell lymphoma undergoing hematopoietic SCT. Bone Marrow Transplant. 2013;48(3):461-462. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical signifi-
107.
2052
haematologica | 2021; 106(8)